



Corres. and Mail

BOX AF

AF/1607
TECH CENTER 1600/2900
JAN 15 2002
RECEIVED

AMENDMENT TRANSMITTAL LETTER		DOCKET NUMBER: P-IX 2947	
SERIAL NO: 09/203,768	FILING DATE: December 2, 1998	EXAMINER: L. Helms	GROUP ART UNIT: 1642
INVENTION: TUMOR SPECIFIC HUMAN MONOCLONAL ANTIBODIES AND METHODS OF USE			

TO COMMISSIONER FOR PATENTS
ATTN: Box AF

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Attention Box AF, Washington, D.C., 20231 on November 5, 2001.

By:

David A. Gay, Reg. No. 39,200

November 5, 2001

Date of Signature

Transmitted herewith is a Response to Final Office Action mailed May 3, 2001, with attached Appendix A, in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☒ Petition for Extension of Time is enclosed (in duplicate).
- ☒ Notice of Appeal from the Examiner to the Board of Patent Appeals and Interferences (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE	
							SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	48	-	48	-	0	x	\$9	\$18	= \$0	\$
INDEPENDENT CLAIMS	14	-	14	-	0	x	\$42	\$84	= \$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			YES		X NO		\$140	\$280	= \$0	\$
							TOTAL ADDITIONAL FEE		\$0	\$

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

Inventors: Watkins and Huse
Serial No.: 09/203,768
Filed: December 2, 1998
Page 2

— Please charge my Deposit Account No. 03-0370 the amount of \$_____. A duplicate copy of this sheet is enclosed.

X A check in the amount of \$620.00 is enclosed, \$160.00 of which covers the fee for filing a Notice of Appeal and \$460.00 of which covers the fee for filing the three-month extension of time.

X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.


X Any additional filing fees required under 37 C.F.R. 1.16.

X Any patent application processing fees under 37 C.F.R. 1.17.

X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

November 5, 2001
Date



David A. Gay
Registration No. 39,200
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
7th Floor
San Diego, California 92122
858-535-9001
USPTO CUSTOMER NO. 23601

RECEIVED

JAN 15 2002

TECH CENTER 1600/2900



PATENT

Our Docket: P-IX 2947

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Watkins and Huse)

Serial No: 09/203,768)

Filed: December 2, 1998)

For: TUMOR SPECIFIC HUMAN)
MONOCLONAL ANTIBODIES)
AND METHODS OF USE)

ATTN: Box AF
Commissioner for Patents
Washington, D.C. 20231

Group Art Unit: 1642

Examiner: L. Helms

I hereby certify that this correspondence
is being deposited with the United States
Postal Service as first class mail in an
envelope addressed to: Commissioner for
Patents, Attention Box AF, Washington,
D.C., 20231 on November 5, 2001.

By: David A. Gay
David A. Gay, Reg. No. 39,200

November 5, 2001
Date of Signature

RESPONSE TO OFFICE ACTION

Responsive to the Office Action mailed May 3, 2001,
entry of the following amendments and remarks is respectfully
requested.

AMENDMENTS

1. A human monoclonal antibody or functional fragment
thereof, comprising at least one Complementarity Determining
Region (CDR) having substantially the amino acid sequence of a
CDR of SEQ ID NO:2 or SEQ ID NO:4, wherein said antibody or
functional fragment thereof specifically binds a neoplastic cell
or antigen thereof.

OK
TO
ENTER
LET
1/23/02
C.1

1/18/02
KD
1-17-02